Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
With a market cap of 126.05B, Vertex Pharmaceuticals(VRTX) trades at $495.92. The stock has a price-to-earnings ratio of 29.62.
On 2026-06-30, Vertex Pharmaceuticals(VRTX) stock traded between a low of $489.62 and a high of $500.99. Shares are currently priced at $495.92, which is +1.3% above the low and -1.0% below the high.
Vertex Pharmaceuticals(VRTX) shares are trading with a volume of 1.74M, against a daily average of 2.45M.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $507.92 and a 52-week low of $362.50.
In the last year, Vertex Pharmaceuticals(VRTX) shares hit a 52-week high of $507.92 and a 52-week low of $362.50.
VRTX News
As per the recent news, Vertex Pharmaceuticals, on June 11, reported new clinical data showing that CASGEVY (exagamglogene autotemcel) delivered efficacy and sa...
In recent sessions, Vertex Pharmaceuticals outperformed the broader market and its sector as investors reacted to optimism around its upcoming earnings report....
Key Points CRISPR Therapeutics AG continues to pioneer gene-editing through its landmark CASGEVY therapy while maintaining a robust cash position. Vertex Phar...
Analyst ratings
81%
of 36 ratingsMore VRTX News
Vertex Pharmaceuticals (VRTX) is back in focus after fresh Phase 3 data for its gene editing therapy CASGEVY in children aged 5 to 11 with severe sickle cell di...
With the Federal Reserve talking tougher on inflation and signaling a possible rate hike within months, investors are rethinking how comfortable they feel with...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.